DYADIC startet

Seite 8 von 11
neuester Beitrag: 24.04.21 12:15
eröffnet am: 04.01.12 19:59 von: buran Anzahl Beiträge: 257
neuester Beitrag: 24.04.21 12:15 von: Annecgala Leser gesamt: 32490
davon Heute: 9
bewertet mit 2 Sternen

Seite: Zurück 1 | ... | 5 | 6 | 7 |
| 9 | 10 | 11 Weiter  

08.04.13 14:33

246516 Postings, 6820 Tage buran.........*R*E*P*O*R*T*

lange Rede kurzer Sinn ..der Kurs sackt zu sehr ..also nicht mehr allzuviel Anteile rausnehmen ..wir wollen auch künftig mit Dyadic Spass haben

kleines Fazit: *KAUFEN*

Bilanz 05-04:
Datum Erster Hoch Tief Schluss     Stücke Volumen
05.04.13 1,75 1,75 1,50  1,50 $ 16.727 25.141

::::::::::RÜHRN ....Mama buran  

08.04.13 15:56

246516 Postings, 6820 Tage burangeeeeeeeht doch:::+16,67% SUPI

Buch dazu

Zeit  Kurs  Stück  
15:31:13 1,75 $  100  
15:31:06 1,50 $  100

buran  

08.04.13 20:14

246516 Postings, 6820 Tage buranRP: +16,00

RTK: 1,74  $ ..getickert sind 10.920 Stücke im Schnelldurchlauf ..die Ticker-max-Leuchte: 1,75 in USD ,GrB  

09.04.13 12:45

246516 Postings, 6820 Tage buranletzte Tafelansicht

1,74 $ +16,00% +0,24 $ In Euro: 1,3347 € | Nasdaq OTC Other buran  

09.04.13 17:28

246516 Postings, 6820 Tage buransieht aus wie ne VO iss aber ne Halte

hier

Zeit  Kurs  Stück  
15:41:20 1,55 $  900

GrB  

10.04.13 21:27

246516 Postings, 6820 Tage buranDyadic International

To Speak At Advanced Biofuels Leadership Conference Panel Discussion15:15 10.04.13


PR Newswire

JUPITER, Fla., April 10, 2013

JUPITER, Fla., April 10, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb, will speak at the Advanced Biofuels Leadership Conference in Washington, DC, during its conference session: Hot Technologies & Products, at 2:30 p.m. EDT on April 17, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

The Advanced Biofuels Leadership Conference has become one of the largest gatherings of CEOs, senior executives, strategic partners, financiers, equity analysts, policymakers and industry suppliers in the Advanced Biofuels & Renewable Chemicals and Biomaterials industries in North America. The conference brings these leaders together to showcase leading companies, technologies and business strategies, and to discuss crucial technologies, partnership, financial strategies, and energy, agricultural, tax and trade policy issues, that together are charting the future of the Biofuels & Renewable Chemicals and Biomaterials industries in the US and Internationally.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

11.04.13 12:54

246516 Postings, 6820 Tage buranBilanz 10-04 im Satz

Datum Erster Hoch Tief Schluss     Stücke Volumen
10.04.13 1,51 1,73 1,50  1,73 $ 3.423 5.222
GrB  

11.04.13 21:43

246516 Postings, 6820 Tage buran30.508 sind durch und ausgeführt

..Sacker bei 1,50 und nen Peng bei 1,74 ..geht voll klar hier ..buran  

17.04.13 22:02

246516 Postings, 6820 Tage buranThread Abgleich

DYADIC International INC. DL-,001 Aktie WKN: A0JK0AISIN: US26745T1016 SKP: +10,53 Pott: +86,67% buran  

10.05.13 10:58

246516 Postings, 6820 Tage buranDanai Brooks Joins Dyadic International

as Chief Operating Officer15:20 07.05.13


PR Newswire

JUPITER, Fla., May 7, 2013

JUPITER, Fla., May 7, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June.  Brooks joins Dyadic from J.P. Morgan where he served as a Vice President in the firm's Investment Bank.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

"Danai has significant financial and operational experience in the renewable energy and bio-based chemical space, and will be a tremendous asset to Dyadic," said Mark Emalfarb, Dyadic's President and Chief Executive Officer.  "As EVP and COO, Danai will play a key role in driving our business development and licensing efforts, as well as corporate strategic planning and operational improvements across the globe."

"As a long-time advisor to Dyadic, I am intimately familiar with the Company and thrilled to have the opportunity to join the team," said Brooks.  "Dyadic continues to compete with larger industrial enzyme companies using its game-changing C1 enzyme expression platform.  Together, we will continue to build commercial momentum through enzyme sales and strategic partnerships across a wide range of sectors including cellulosic biofuels, biopharmaceuticals and industrial applications.  We look forward to introducing new C1-based products to the many industries and companies that can benefit from C1's ability to produce enzymes and other proteins with class leading performance."

While at J.P. Morgan, Brooks advised clients across a broad spectrum of sectors, including chemicals, renewable energy and industrials.  He has held senior operational, engineering and manufacturing positions with Dell Inc., Mars Inc. and Ford Motor Company.  He received a B.S. in Industrial Engineering and Master of Engineering from Cornell University, a Master of Engineering Management from Northwestern University and an MBA from Northwestern's Kellogg School of Management.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

10.05.13 10:59

246516 Postings, 6820 Tage buranDyadic International To Announce First Quarter

2013 Financial Results And Host Conference Call On Wednesday, May 15, 201316:00 08.05.13


PR Newswire

JUPITER, Fla., May 8, 2013

JUPITER, Fla., May 8, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the first quarter ended March 31, 2013 after market close on Wednesday, May 15, 2013 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

In order to participate in the live session, please use the following dial-in numbers five to ten minutes prior to start time:

Calling from the United States or Canada:  800-289-0517

Calling from other countries:  913-981-5556

Confirmation Code:  2781568

A replay of the conference call will be available on Dyadic's website (www.dyadic.com) within 24 hours after the live event.

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

10.05.13 11:00

246516 Postings, 6820 Tage buranDyadic

is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

GrB  

14.05.13 15:18

246516 Postings, 6820 Tage buranSatz 13-05

Datum Erster Hoch Tief Schluss     Stücke Volumen
13.05.13 1,87 1,96 1,87  1,96 $ 1.700 3.190
GrB  

14.05.13 20:56

246516 Postings, 6820 Tage buranRTK 1,90 USD

Zeit  Kurs  Stück  
20:20:57 1,90 $  3.400  
20:20:36 1,90 $  600  
20:12:36 1,90 $  1.000  
18:14:56 2,00 $  25.000  
18:09:33 2,00 $  5.900  
17:57:43 2,00 $  2.522  
17:56:51 2,00 $  4.900  
17:56:29 2,00 $  100  
17:56:28 2,00 $  750  
17:56:26 2,00 $  2.000  
17:55:15 1,99 $  3.785  
17:54:14 1,99 $  4.500  
17:49:07 1,99 $  5.000  
17:42:35 1,99 $  500  
17:42:23 1,98 $  100  
17:41:54 1,99 $  5.000  
17:40:29 1,99 $  770  
17:40:14 2,00 $  3.000  
17:18:13 1,99 $  394  
15:40:12 1,99 $  100  
15:30:59 1,88 $  700  
15:30:11 1,88 $  200  

15.05.13 15:14

246516 Postings, 6820 Tage buranBASF And Dyadic

International Enter Into A Research And License Agreement14:35 15.05.13


PR Newswire

LUDWIGSHAFEN, Germany and JUPITER, Fla., May 15, 2013

LUDWIGSHAFEN, Germany and JUPITER, Fla., May 15, 2013 /PRNewswire/ -- BASF (BAS.DE) and Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI) announced today that the two Companies have entered into a non-exclusive worldwide research and license agreement.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

(Logo: http://photos.prnewswire.com/prnh/20130515/CL13970LOGO )

Under the terms of the agreement, BASF will be able to use Dyadic's patented and proprietary C1 platform technology to develop, produce, distribute and sell industrial enzymes in certain fields for a variety of applications.  BASF will fund research and development at Dyadic's research lab in The Netherlands. In addition to this funding, BASF has agreed to pay Dyadic a $6 million upfront license fee, and certain research and commercial milestone fees, as well as royalties upon commercialization.

"Dyadic's C1 technology will strengthen BASF's position in the industrial enzyme industry," said Dr. Carsten Sieden, Senior Vice President Fine Chemicals and Biocatalysis Research, BASF.  "We expect this license agreement with Dyadic to result in promising long-term opportunities."

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "Empowering BASF, the world's leading chemical company, with our C1 technology provides them with access to a commercially-proven industrial enzyme production platform.  In using its vast resources to develop, manufacture and sell new products from the C1 platform, BASF will have business opportunities for a variety of markets, including animal and human nutrition. This transaction will have long-lasting effects on the industrial enzyme businesses of both Dyadic and BASF."

Emalfarb concluded, "Dyadic looks forward to working with BASF and utilizing our C1 technology for the expression of next-generation enzyme products for a range of applications.  This collaboration is yet another example of Dyadic's ability to leverage our technologies in a variety of industries."

About BASF

BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. We combine economic success with environmental protection and social responsibility. Through science and innovation, we enable our customers in nearly every industry to meet the current and future needs of society. Our products and solutions contribute to conserving resources, ensuring nutrition and improving quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF had sales of ¤72.1 billion in 2012 and more than 110,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN).

Further information on BASF is available on the Internet at www.basf.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

19.05.13 11:11

246516 Postings, 6820 Tage buranwir spielen nicht um Geld

:::::wir nehmen es uns ...::2,00 $ +4,71% +0,09 $

In Euro: 1,5582 € | Nasdaq OTC Other, 17.05.13

buran  

22.05.13 08:02

246516 Postings, 6820 Tage buranEuro: 1,3866 € / Nasdaq OTC Other

1,79 $ +2,29% +0,04 $ , 21.05.13 , GrB ..Spiel Spass Abenteuer ..hier gib's alles zum toben und spielen:: DYADIC  

22.05.13 17:02

246516 Postings, 6820 Tage buranmöhre ät möhre ät röm töm töm töm

Zeit  Kurs  Stück  
16:04:36 1,91 $  100  
15:57:36 1,85 $  1.030  
15:57:30 1,89 $  130  
15:57:13 1,91 $  120  
15:39:42 1,85 $  1.100  
15:30:10 1,91 $  2.000
___________________

..nimm mal lieber die Möhrchen ..HAMMER  

30.05.13 06:54

246516 Postings, 6820 Tage buranDyadic International To Present

At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech15:50 29.05.13


PR Newswire

JUPITER, Fla., May 29, 2013

JUPITER, Fla., May 29, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), announced today that its President and CEO, Mark Emalfarb, will present at the World Biotechnology Congress 2013 in Boston, Massachusetts and the BIO World Congress on Industrial Biotech in Montreal, Canada.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic is a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Emalfarb's presentation at the World Biotechnology Congress will take place on June 6th, from 11:20 – 11:40 a.m. EDT, in Lecture Hall No. 201 (Level 2) at the John B. Hynes Veterans Memorial Convention Center.

Titled "Dyadic's C1 Enzyme Technology Update: On the Road to Cellulosic Sugars for Fuels and Chemicals," Emalfarb will discuss Dyadic's license agreements, commercial developments and progress toward producing cost-competitive cellulosic biofuels from agricultural byproducts such as corn stover and wheat straw.

Emalfarb will also co-chair the Industrial and Manufacturing session scheduled for Thursday, June 6th, from 2:00 – 5:10 p.m. EDT in Lecture Hall No. 201.  The session will feature presentations on next-generation biofuels and new routes toward the development of novel antifungal therapeutics, among others.

At the BIO World Congress on Industrial Biotech on June 18th, Emalfarb will participate on a panel called "Global Benefits for Synthetic Biology Tools" from 10:30 a.m. – 12:00 p.m. EDT at the Palais des Congres de Montreal.

"Dyadic is making significant progress towards producing economically viable cellulosic biofuels and chemicals from C1-derived enzymes," said Emalfarb.  "For instance, we expect that our C1 platform will be used to produce enzymes in commercial volumes when Abengoa Energy starts up its commercial scale cellulosic ethanol biorefinery in Hugoton, Kansas later this year."

Emalfarb continued, "We look forward to providing an update on this and other commercial developments at both of these internationally recognized scientific conferences."

About World Biotechnology Congress 2013

The World Biotechnology Congress 2013 will focus on various important disciplines of biotechnology and its applications for improvement in health and quality of life the world over.  It is anticipated that up to 1000 of the world's leading scientists, researchers, industrialists and academicians, including several Nobel Laureates, in the fields of biotechnology as well as medical and biological sciences, will attend this forum in Boston, to share and discuss new scientific ideas, products and breakthroughs.

About BIO World Congress

The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event for business leaders, investors, and policy makers in biofuels, bio-based products, and renewable chemicals.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

05.06.13 15:51

246516 Postings, 6820 Tage buranKAUF ausgeführt

Der Beleg

Zeit  Kurs  Stück  
15:30:06 1,88 $  300

GRATULATION ..Sie sind jetzt stolzer Dyadic Anteilshaber
Es bediente Sie die Börse Nasdaq  

13.06.13 16:16

246516 Postings, 6820 Tage buranEuro: 1,4279 € / Nasdaq OTC Other

03.07.13 12:34

246516 Postings, 6820 Tage buranviele viele Stücke ..Riesenvolumen 88 T

Datum Erster Hoch Tief Schluss     Stücke Volumen
02.07.13 1,60 1,65 1,56  1,63 $ 55.255 88 T
GrB  

04.07.13 16:49

246516 Postings, 6820 Tage buranEuro: 1,3097 € / Nasdaq OTC Other / SKP 3,68

1,69 $ +3,68% +0,06 $ , 03.07.13 , Pott +87,78% , GrB  

06.08.13 14:36

246516 Postings, 6820 Tage buranDyadic International To Announce Second Quarter

2013 Financial Results And Host Conference Call On Thursday, August 8, 201314:30 31.07.13


PR Newswire

JUPITER, Fla., July 31, 2013

JUPITER, Fla., July 31, 2013 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the second quarter ended June 30, 2013 after market close on Thursday, August 8, 2013 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

In order to participate in the live session, please use the following dial-in numbers five to ten minutes prior to start time:

Calling from the United States or Canada:  888-204-4520

Calling from other countries:  913-312-0711

Confirmation Code:  8083027

A replay of the conference call will be available on Dyadic's website (www.dyadic.com) within 24 hours after the live event.

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

08.08.13 09:00

246516 Postings, 6820 Tage burander Chart ist hart

Datum Erster Hoch Tief Schluss     Stücke Volumen
07.08.13 1,99 1,99 1,89  1,95 $ 76.490 148 T

bist Du zu schwach ..gehst Du runter den Börsenbach ..schwimm immer gegen den Strom ..ja Du als Fisch ..aber nicht als Börsenfisch ..aber das wussest Du ja schon

Börsen Forelle buran  

Seite: Zurück 1 | ... | 5 | 6 | 7 |
| 9 | 10 | 11 Weiter  
   Antwort einfügen - nach oben